<DOC>
	<DOCNO>NCT01178528</DOCNO>
	<brief_summary>Patients heart failure ( HF ) limit exercise tolerance , pharmacological intervention proven effective improve exercise capacity . At presence conflict evidence effectiveness beta-blockers exercise capacity . Ivabradine show improve prognosis patient ischemic heart disease , leave ventricular dysfunction heart rate &gt; 70 bpm . The association ivabradine atenolol proven effective increase exercise tolerance patient ischemic heart disease . Aim present study evaluate effect heart rate reduction ivabradine , carvedilol combination patient heart failure ischemic origin .</brief_summary>
	<brief_title>Heart Rate Reduction Heart Failure</brief_title>
	<detailed_description>Patients chronic heart failure ischemic origin ( 120 ) Stable coronary artery disease Acute coronary syndrome &gt; 3 month Revascularization procedures &gt; 3 month Naive heart rate reduce agent New York Heart Association ( NYHA ) Class II III 6 minute walk test ( 6MW ) tolerance 200 400 Stable medication past 3 month Treatment Ivabradine 7.5 mg b.i.d . Carvedilol 25 mg b.i.d . Carvedilol Ivabradine 12.5/5 mg b.i.d . Efficacy measure Intention treat Exercise tolerance Quality life</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>heart failure IIIII ischemic origin stable medication least 3 month &gt; 3 month acute ischemic syndrome revascularization procedure naive heart rate reduce agent bradycardia hypersensitivity contraindication study drug exercise tolerance 6 minute walk test &lt; 100 &gt; 400</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>heart failure</keyword>
	<keyword>heart rate</keyword>
	<keyword>ivabradine</keyword>
	<keyword>carvedilol</keyword>
</DOC>